Yes, it’s interesting that ACAD has risen 16% over the past month, compared with a drop of 2.5% on the Nasdaq Biotech Index.
It’s also interesting to compare ACAD’s share price movement over this past month with the month post-Daybue approval, when the share price dropped 12%. I gained the impression from the post-approval conference that analysts believed that Daybue’s high pricing would negatively impact patient demand.
I suspect those analysts are now seeing early interest in and take-up of Daybue that has exceeded their (typically low) expectations.
Acadia, page-299
-
- There are more pages in this discussion • 379 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |